In STAD, patients exhibiting high TRAF6 expression were associated with a worse prognosis, while those with elevated TRAF2 and TRAF4 expressions had a more favorable prognosis compared to individuals with low expression levels (Fig. 5N). This evidence concerns the gene TRAF6 and gastric adenocarcinoma.